Abstract
This review article deals with the role of beta blockade in the limitation of infarct development. A large number of studies have reported that early administration of beta blockers limits infarct size in animals. In a few, however, these results were not reconfirmed. In man, several large randomized trials have shown that early administration of beta blockade limits infarct development judged from serum enzyme activity and ECG recordings. Delay time between the onset of symptoms and start of treatment is of major importance. It appears as though patients with a higher initial rate pressure product respond most favourably. Although these results are encouraging, the role of infarct limitation in relation to effects on early mortality, chest pain and arrhythmias have not been clearly defined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
